| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| bms-986020 | lysophosphatidic acid receptor 1 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Systemic Scleroderma[MeSHID:D012595] Psoriasis[MeSHID:D011565] Scleroderma[MeSHID:D012594] |
127.3 | phase 2 | antagonist |
| bms-986020 | lysophosphatidic acid receptor 1 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Systemic Scleroderma[MeSHID:D012595] Psoriasis[MeSHID:D011565] Scleroderma[MeSHID:D012594] |
127.3 | phase 2 | unknown |
| click here to return to the previous page | ||||||||